Researchers claim they’ve found a way to fight previously untreatable high blood pressure.
People who took a new drug during a clinical trial were found to have significantly lower blood pressure after other conventional drugs had failed.
Researchers from Queen Mary University of London and colleagues from the US pharmaceutical company CinCor looked at whether 248 patients would benefit from taking a drug called baxdrostat.
The drug works by preventing the body from making aldosterone — a hormone that helps regulate the amount of salt in the body.
Patients with “treatment-resistant” high blood pressure received either a placebo or variable doses of the drug for 12 weeks.
The study, published in New England Journal of Medicine and presented at the American Heart Association Scientific Sessions conference in the US, found that people who received the highest dose had an average reduction in blood pressure of 20 points.
Those taking smaller doses also saw a drop in blood pressure – with the highest doses being associated with the highest reductions.
“The results of this novel drug are exciting, although more testing is needed before we can make comparisons to existing drugs,” said Professor Morris Brown, co-author of the study and Professor of Endocrine Hypertension at Queen Mary University of London.
“But baxdrostat could potentially bring hope to many people who don’t respond to traditional treatments for high blood pressure.”
Meanwhile, a separate study, also being presented at the conference, has found that doctors working in the NHS may be able to improve their heart disease risk assessment tools by also using genetic blood tests.
Researchers from North of England Care System Support, in collaboration with the NIHR Clinical Research Network and Genomics plc, investigated whether improvements could be made to any of the current risk assessment tools used to check a person’s risk for cardiovascular disease.
The tool gives patients a score based on their blood pressure, cholesterol levels, body mass index, age, gender, and family history.
Statins may be offered to high-risk patients to try to reduce their risk.
The researchers wanted to gauge whether adding a person’s polygenic risk score — checking their genetic risk score through a blood or saliva test — would lead to improvements in risk scores.
In the study, around 800 people were examined using the new method.
The study found that 24 percent of participants had clinically significant changes in their cardiovascular disease risk when genetic information was added to current risk assessment tools.
https://www.independent.ie/news/researchers-say-new-drug-could-be-cure-for-high-blood-pressure-42126350.html Researchers say a new drug could be a cure for high blood pressure